Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia

Hanny Al-Samkari

Department of Medicine, Massachusetts General Hospital, Boston

Josefien Hessels

Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands

Antoni Riera-Mestre

Department of Internal Medicine, Hospital Universitari de Bellvitge–Institut d’Investigació Biomèdica de Bellvitge, L’Hospitalet de Llobregat, Spain

Sophie Dupuis-Girod

Genetic Department, Hôpital Femme–Mère–Enfant, Hospices Civils de Lyon, Bron, France

Thibaut Van Zele

Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium

Vicente Gómez del Olmo

Internal Medicine Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid

Pamela G. Hodges

Division of Hematology–Oncology, Massachusetts General Hospital, Harvard Medical School, Boston

Raquel Torres-Iglesias

Department of Internal Medicine, Hospital Universitari de Bellvitge–Institut d’Investigació Biomèdica de Bellvitge, L’Hospitalet de Llobregat, Spain

Roberto Bertè

Gastroenterology Department, Azienda Socio-Sanitaria Territoriale, Ospedale Maggiore Crema, Crema, Italy

Pierre Saint-Mezard

Vaderis Therapeutics, Basel, Switzerland

Hedvika Lazar

Vaderis Therapeutics, Basel, Switzerland

Nicholas Benedict

Vaderis Therapeutics, Basel, Switzerland

Debra Barker

Vaderis Therapeutics, Basel, Switzerland

Corrado Bernasconi

Vaderis Therapeutics, Basel, Switzerland

Damien Picard

Vaderis Therapeutics, Basel, Switzerland

Elisabetta Buscarini

Gastroenterology Department, Azienda Socio-Sanitaria Territoriale, Ospedale Maggiore Crema, Crema, Italy

Hans-Jurgen Mager

Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands